Veracyte, Inc. (VCYT) stock
Close on Nov 18, 2026Market cap $2.06BP/E 18.3Yield –
Earnings
Veracyte's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Veracyte's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 24, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 4, 2026after the close | $151.80M | +15.1% | $0.38 | $0.51 | Release |
| Q2 FY2026ended Jun 30, 2026 | Jul 30, 2026during market hours | $150.30M | +15.4% | $0.31 | $0.54 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 5, 2026during market hours | $139.10M | +21.5% | $0.35 | $0.52 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 25, 2026during market hours | $140.60M | +18.5% | $0.51 | $0.53 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 4, 2025during market hours | $131.90M | +13.8% | $0.24 | $0.51 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 6, 2025during market hours | $130.20M | +13.8% | -$0.01 | $0.44 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 7, 2025during market hours | $114.50M | +18.3% | $0.09 | $0.31 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 24, 2025during market hours | $118.60M | +20.8% | $0.06 | $0.36 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 6, 2024during market hours | $115.90M | +28.6% | $0.19 | $0.33 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 6, 2024during market hours | $114.40M | +26.7% | $0.07 | $0.30 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 7, 2024during market hours | $96.80M | +17.5% | -$0.02 | – | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 22, 2024during market hours | $98.20M | +22.3% | -$0.39 | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 7, 2023during market hours | $90.10M | +19.2% | -$0.41 | – | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 8, 2023during market hours | $90.30M | +23.9% | -$0.12 | – | Release |
| Q1 FY2023ended Mar 31, 2023 | May 4, 2023during market hours | $82.40M | +21.5% | -$0.11 | – | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 22, 2023during market hours | $80.30M | +19.3% | -$0.05 | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 2, 2022during market hours | $75.60M | +25.2% | -$0.12 | – | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 2, 2022during market hours | $72.90M | – | -$0.13 | – | Release |
| Q1 FY2022ended Mar 31, 2022 | May 3, 2022during market hours | $67.80M | – | -$0.20 | – | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 28, 2022during market hours | $67.30M | – | -$0.15 | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 9, 2021during market hours | $60.40M | – | -$0.20 | – | Release |
| Q2 FY2021ended Jun 30, 2021 | Jul 29, 2021during market hours | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | Apr 15, 2021during market hours | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 3, 2021before the open | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 2, 2020during market hours | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Veracyte's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| total revenue | FY2026 | $590.00M – $596.00M | $582.00M – $592.00M | Raised | Jul 30, 2026 |
| total revenueGAAP | FY2026 | $570.00M – $582.00M | – | New | Feb 25, 2026 |
| total revenue growth | FY2026 | +14% – +15% | +13% – +14% | Lowered | Jul 30, 2026 |
| total revenue guidance | FY2026 | $590.00M – $593.00M | – | New | Nov 4, 2026 |
| adjusted EBITDA marginnon-GAAP | FY2026 | 26% | – | New | May 5, 2026 |
| adjusted EBITDA marginnon-GAAP | FY2026 | 26% | 25% | Raised | Nov 4, 2026 |
| adjusted EBITDA marginnon-GAAP | FY2026 | 26% | – | New | Jul 30, 2026 |
| adjusted EBITDA marginnon-GAAP | FY2026 | 25% | – | New | Jan 12, 2026 |
| testing revenue | FY2026 | $576.00M – $582.00M | – | New | Jul 30, 2026 |
| testing revenue growth | FY2026 | +17% – +18% | – | New | Jul 30, 2026 |
Guidance vs results
The last range Veracyte gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Revenue | $484.00M – $487.00M | $517.20MΣ4Q | Above range |
| FY2025 | Revenue growth | +16% | +16.04%Σ4Q | Within range |
Guidance history
Every forecast Veracyte put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 4, 2026 | adjusted EBITDA margin | FY2026 | 26% | Raised |
| Nov 4, 2026 | total revenue guidance | FY2026 | $590.00M – $593.00M | New |
| Jul 30, 2026 | adjusted EBITDA margin | FY2026 | 26% | New |
| Jul 30, 2026 | testing revenue growth | FY2026 | +17% – +18% | New |
| Jul 30, 2026 | testing revenue | FY2026 | $576.00M – $582.00M | New |
| Jul 30, 2026 | total revenue growth | FY2026 | +14% – +15% | Lowered |
| Jul 30, 2026 | total revenue | FY2026 | $590.00M – $596.00M | Raised |
| May 5, 2026 | adjusted EBITDA margin | FY2026 | 26% | New |
| May 5, 2026 | total revenue growth | FY2026 | +13% – +14% | Lowered |
| May 5, 2026 | testing revenue growth | FY2026 | +16% – +18% | Raised |
| May 5, 2026 | total revenue | FY2026 | $582.00M – $592.00M | Raised |
| May 5, 2026 | testing revenue | FY2026 | $570.00M – $580.00M | Lowered |
| Feb 25, 2026 | adjusted EBITDA margin | FY2026 | 25% | New |
| Feb 25, 2026 | total revenue | FY2026 | $570.00M – $582.00M | New |
| Jan 12, 2026 | adjusted EBITDA margin | FY2026 | 25% | New |
| Jan 12, 2026 | total revenue guidance | FY2026 | +10% – +13% | New |
| Jan 12, 2026 | testing revenue guidance | FY2026 | +14% – +16% | Raised |
| Jan 12, 2026 | total revenue guidance | FY2026 | $570.00M – $582.00M | New |
| Jan 12, 2026 | testing revenue guidance | FY2026 | $559.00M – $569.00M | Lowered |
| Nov 4, 2025 | adjusted EBITDA as a percentage of revenue | FY2025 | 25% | New |
| Nov 4, 2025 | testing revenue growth | FY2025 | +16% | New |
| Nov 4, 2025 | total revenue growth | FY2025 | +14% | Lowered |
| Nov 4, 2025 | testing revenue | FY2025 | $484.00M – $487.00M | New |
| Nov 4, 2025 | total revenue | FY2025 | $506.00M – $510.00M | Raised |
| Aug 6, 2025 | adjusted EBITDA as a percentage of revenue | FY2025 | 23.5% | Raised |
| Aug 6, 2025 | testing revenue growth | FY2025 | +14% – +15% | Raised |
| Aug 6, 2025 | total revenue growth | FY2025 | +11% – +13% | Lowered |
| Aug 6, 2025 | testing revenue | FY2025 | $477.00M – $483.00M | Raised |
| Aug 6, 2025 | total revenue | FY2025 | $496.00M – $504.00M | Raised |
| May 7, 2025 | adjusted EBITDA as a percentage of revenue | FY2025 | 22.5% | New |
| May 7, 2025 | testing revenue guidance year-over-year growth | FY2025 | +12% – +15% | Reaffirmed |
| May 7, 2025 | testing revenue guidance | FY2025 | $470.00M – $480.00M | Reaffirmed |
| Feb 24, 2025 | adjusted EBITDA as a percentage of revenue | FY2025 | 21.6% | New |
| Feb 24, 2025 | testing revenue year-over-year growth | FY2025 | +12% – +15% | New |
| Feb 24, 2025 | testing revenue | FY2025 | $470.00M – $480.00M | New |
| Nov 6, 2024 | cash, cash equivalents and short-term investments | FY2024 | $280.00M – $285.00M | Raised |
| Nov 6, 2024 | total revenue | FY2024 | $442.00M – $445.00M | Raised |
| Nov 6, 2024 | total revenue year-over-year growth | FY2024 | +22% – +23% | New |
| Nov 6, 2024 | testing revenue growth | FY2024 | +28% | Raised |
| Aug 6, 2024 | cash, cash equivalents and short-term investments | FY2024 | $260.00M – $270.00M | Raised |
| Aug 6, 2024 | total revenue | FY2024 | $432.00M – $438.00M | Raised |
| May 7, 2024 | testing growth | FY2024 | +15% – +18% | Raised |
| May 7, 2024 | cash, cash equivalents and short-term investments | FY2024 | $236.00M – $240.00M | Raised |
| May 7, 2024 | total revenue | FY2024 | $402.00M – $410.00M | Raised |
| Feb 22, 2024 | cash, cash equivalents and short-term investments | FY2024 | $230.00M – $234.00M | New |
| Feb 22, 2024 | total revenue | FY2024 | $394.00M – $402.00M | Reaffirmed |
| Jan 8, 2024 | testing and product revenue | FY2024 | +13% – +15% | New |
| Jan 8, 2024 | cash, cash equivalents and short-term investments ending balance | FY2024 | +10% – +12% | Lowered |
| Jan 8, 2024 | total company revenue | FY2024 | $394.00M – $402.00M | New |
| Nov 7, 2023 | total revenue | FY2023 | $352.00M – $354.00M | Raised |
| Aug 8, 2023 | total revenue | FY2023 | $342.00M – $350.00M | Raised |
| May 4, 2023 | total revenue | FY2023 | $330.00M – $340.00M | Raised |
| Feb 22, 2023 | total revenue | FY2023 | $325.00M – $335.00M | New |
| Nov 2, 2022 | total revenue | FY2022 | $288.00M – $293.00M | Raised |
| Aug 2, 2022 | total revenue | FY2022 | $272.00M – $280.00M | Raised |
| May 3, 2022 | total revenue | FY2022 | $265.00M – $275.00M | Raised |
| Feb 28, 2022 | annual total revenue | FY2022 | $260.00M – $275.00M | New |
| Nov 9, 2021 | annual total revenue | FY2021 | $210.00M – $218.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Veracyte filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
See a number that looks wrong?